Your browser doesn't support javascript.
loading
Recent advances and impending challenges for the radiopharmaceutical sciences in oncology.
Lapi, Suzanne E; Scott, Peter J H; Scott, Andrew M; Windhorst, Albert D; Zeglis, Brian M; Abdel-Wahab, May; Baum, Richard P; Buatti, John M; Giammarile, Francesco; Kiess, Ana P; Jalilian, Amirreza; Knoll, Peter; Korde, Aruna; Kunikowska, Jolanta; Lee, Sze Ting; Paez, Diana; Urbain, Jean-Luc; Zhang, Jingjing; Lewis, Jason S.
Afiliação
  • Lapi SE; Departments of Radiology and Chemistry, O'Neal Comprehensive Cancer Center, University of Alabama, Birmingham, AL, USA.
  • Scott PJH; Department of Radiology, University of Michigan, Ann Arbor, MI, USA.
  • Scott AM; Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC, Australia; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia; School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia; Department of Surgery, Faculty of Medicine, University of Melbour
  • Windhorst AD; Department of Radiology & Nuclear Medicine, Amsterdam UMC, Amsterdam, Netherlands; Cancer Center Amsterdam, Vrije Universiteit, Amsterdam, Netherlands.
  • Zeglis BM; Department of Chemistry, Hunter College, City University of New York, New York City, NY, USA; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York City, NY, USA; Department of Radiology, Weill Cornell Medical College, New York City, NY, USA.
  • Abdel-Wahab M; Division of Human Health, Department of Nuclear Sciences and Applications, International Atomic Energy Agency, Vienna, Austria.
  • Baum RP; Deutsche Klinik für Diagnostik (DKD Helios Klinik) Wiesbaden, Curanosticum MVZ Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, Germany.
  • Buatti JM; Department of Radiation Oncology, University of Iowa Carver College of Medicine, Iowa City, IA, USA.
  • Giammarile F; Nuclear Medicine and Diagnostic Imaging Section, Division of Human Health, Department of Nuclear Sciences and Applications, International Atomic Energy Agency, Vienna, Austria; Centre Leon Bérard, Lyon, France.
  • Kiess AP; Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Jalilian A; Radiochemistry and Radiotechnology Section, Division of Physical and Chemical Sciences, Department of Nuclear Sciences and Applications, International Atomic Energy Agency, Vienna, Austria.
  • Knoll P; Dosimetry and Medical Radiation Physics Section, Division of Human Health, Department of Nuclear Sciences and Applications, International Atomic Energy Agency, Vienna, Austria.
  • Korde A; Radiochemistry and Radiotechnology Section, Division of Physical and Chemical Sciences, Department of Nuclear Sciences and Applications, International Atomic Energy Agency, Vienna, Austria.
  • Kunikowska J; Nuclear Medicine Department, Medical University of Warsaw, Warsaw, Poland.
  • Lee ST; Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC, Australia; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia; School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia; Department of Surgery, Faculty of Medicine, University of Melbour
  • Paez D; Nuclear Medicine and Diagnostic Imaging Section, Division of Human Health, Department of Nuclear Sciences and Applications, International Atomic Energy Agency, Vienna, Austria.
  • Urbain JL; Department of Radiology-Nuclear Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
  • Zhang J; Department of Diagnostic Radiology, National University of Singapore, Singapore; Clinical Imaging Research Centre, Nanomedicine Translational Research Program, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
  • Lewis JS; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York City, NY, USA; Department of Radiology, Weill Cornell Medical College, New York City, NY, USA; Department of Pharmacology, Weill Cornell Medical College, New York City, NY, USA. Electronic address: lewisj2@mskcc.org.
Lancet Oncol ; 25(6): e236-e249, 2024 Jun.
Article em En | MEDLINE | ID: mdl-38821098
ABSTRACT
This paper is the first of a Series on theranostics that summarises the current landscape of the radiopharmaceutical sciences as they pertain to oncology. In this Series paper, we describe exciting developments in radiochemistry and the production of radionuclides, the development and translation of theranostics, and the application of artificial intelligence to our field. These developments are catalysing growth in the use of radiopharmaceuticals to the benefit of patients worldwide. We also highlight some of the key issues to be addressed in the coming years to realise the full potential of radiopharmaceuticals to treat cancer.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Compostos Radiofarmacêuticos / Neoplasias Idioma: En Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Compostos Radiofarmacêuticos / Neoplasias Idioma: En Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos